Cytosolic 5′-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis

Annals of the Rheumatic Diseases

Volumn 76, Issue 5, 2017, Pages 862-868

  Lilleker, J B ^a,b   Rietveld, A ^c   Pye, S R ^a   Mariampillai, K ^d   Benveniste, O ^d   Peeters, M T J ^c   Miller, J A L ^e   Hanna, M G ^f   MacHado, P M ^f,g   Parton, M J ^f   Gheorghe, K R ^h   Badrising, U A ⁱ   Lundberg, I E ^h   Sacconi, S ^j   Herbert, M K ^k   McHugh, N J ^l   Lecky, B R F ^m   Brierley, C ⁿ   Hilton Jones, D ^o   Lamb, J A ^a   Roberts, M E ^b   Cooper, R G ^a,b,p   Saris, C G J ^c   Pruijn, G J M ^k   Chinoy, H ^a,b,q   Van Engelen, B G M ^c   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c RADBOUD UNIVERSITY   (Netherlands)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITÉ CÔTE D'AZUR   (France)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l University of Bath   (United Kingdom)

^m THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

ⁿ CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^o OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^p UNIVERSITY OF LIVERPOOL   (United Kingdom)

^q MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Autoantibodies; Dermatomyositis; Polymyositis

Indexed keywords

5' NUCLEOTIDASE; AUTOANTIBODY; BIOLOGICAL MARKER; CYTOCHROME C OXIDASE; NT5C1A PROTEIN, HUMAN;

AGED; BLOOD; CHEMISTRY; CYTOSOL; FEMALE; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MYOSITIS, INCLUSION BODY; ONSET AGE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SELF HELP DEVICE; SKELETAL MUSCLE CELL; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME FACTOR; VERY ELDERLY;

5'-NUCLEOTIDASE; AGE OF ONSET; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOMARKERS; CYTOSOL; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUSCLE FIBERS, SKELETAL; MUSCLE WEAKNESS; MYOSITIS, INCLUSION BODY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SELF-HELP DEVICES; SURVIVAL RATE; TIME FACTORS;

EID: 85011409962     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210282     Document Type: Article

References (26)

1. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusionbody myositis in the Netherlands: A nationwide study. Neurology 2000;55:1385-7.
2. Wilson FC, Ytterberg SR, St Sauver JL, et al. Epidemiology of sporadic inclusionbody myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol2008;35:445-7.
3. Benveniste O, Stenzel W, Hilton-Jones D, et al. Amyloid deposits andinflammatory infiltrates in sporadic inclusion body myositis: The inflammatoryegg comes before the degenerative chicken. Acta neuropathol 2015;129:611-24.
4. Mastaglia FL, Needham M. Inclusion body myositis: A review of clinical and geneticaspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci2015;22:6-13.
5. Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inflammatory myopathy:clinical characteristics, treatment strategies, outcome in 62 patients. Mayo ClinProc 2007;82:441-7.
6. Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusionbody myositis: An end stage with major disabilities. Brain 2011;134(Pt 11):3167-75.
7. Rose MR, McDermott MP, Thornton CA, et al. A prospective natural historystudy of inclusion body myositis: Implications for clinical trials. Neurology2001;57:548-50.
8. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study ofsporadic inclusion body myositis. Brain 2011;134(Pt 11):3176-84.
9. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
10. Hilton-Jones D, Miller A, Parton M, et al. Inclusion body myositis: MRC Centre forNeuromuscular Diseases, IBM workshop, London, 13 June 2008. NeuromusculDisord 2010;20:142-7.
11. Verschuuren JJ, Badrising UA, Van Engelen BG, et al. Inclusion body myositis. In:Emery AEH, ed. Diagnostic criteria for neuromuscular disorders. London: RoyalSociety of Medicine Press, 1997:81-4.
12. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis ofinclusion body myositis independently of pathological features. J Neurol NeurosurgPsychiatry 2013;84:1240-6.
13. Felice KJ, North WA. Inclusion body myositis in Connecticut: Observations in 35patients during an 8-year period. Medicine (Baltimore) 2001;80:320-7.
14. Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying theprincipal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open 2014;4:e004552.
15. Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadicinclusion body myositis: Implications for clinical trials. Neuromuscul Disord2013;23:404-12.
16. Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic50-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397-407.
17. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscleprotein in inclusion body myositis. PLoS ONE 2011;6:e20266.
18. Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1A antibody in sporadicinclusion body myositis predicts more severe motor, bulbar and respiratoryinvolvement. J Neurol Neurosurg Psychiatry 2016;87:373-8.
19. Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 50-nucleotidase 1Aautoimmunity in sporadic inclusion body myositis. Ann Neurol2013;73:408-18.
20. Rothwell S, Cooper RG, Lundberg IE, et al. Dense genotyping of immune-relatedloci in idiopathic inflammatory myopathies confirms HLA alleles as the strongestgenetic risk factor and suggests different genetic background for major clinicalsubgroups. Ann Rheum Dis 2016;75:1558-66.
21. Lundberg IE, Svensson J. Registries in idiopathic inflammatory myopathies. CurrOpin Rheumatol 2013;25:729-34.
22. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity ofautoantibodies to cytosolic 50-nucleotidase 1A in sporadic inclusion bodymyositis versus known autoimmune diseases. Ann Rheum Dis2016;75:696-701.
23. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies injuvenile dermatomyositis identify a distinct clinical phenotype: A prospective cohortstudy. Arthritis Res Ther 2014;16:R138.
24. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 50-nucleotidase 1Aas a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res2016;68:66-71.
25. Limaye VS, Lester S, Blumbergs P, et al. Anti-C N1A antibodies in SouthAustralian patients with inclusion body myositis. Muscle Nerve2016;53:654-5.
26. Herbert MK, Pruijn GJ. Novel serology testing for sporadic inclusion bodymyositis: Disease-specificity and diagnostic utility. Curr Opin Rheumatol2015;27:595-600.